Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Disitamab vedotin-toripalimab led to a significantly greater improvement in outcomes than chemotherapy among patients with untreated HER2-expressing locally advanced or metastatic urothelial cancer. (Funded by RemeGen and others; RC48-C016 ClinicalTrials.gov number, NCT05302284; ChinaDrugTrials.org.cn number, CTR20220348.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-10-19
DOI
https://doi.org/10.1056/nejmoa2511648
Citations
27
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
54.17
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Cuijian Zhang, Haitao Niu, Guoxian Ma, Kai Yao et al.
27 citations
New England Journal of Medicine
Bladder and Urothelial Cancer Treatments
54.17
article

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Cuijian Zhang, Haitao Niu, Guoxian Ma, Kai Yao, Xiaolong Qi, Baiye Jin, Jianmin Fang, Xinan Sheng, Gongqian Zeng, Yanxia Shi, Xue‐Yi Xue, Jian Gu, Zhisong He, Jiasheng Bian, Zhixian Yu, Beisong Liu, Peng Zhao, Xin Gou, Qin Yang, Tiejun Yang, Lu Zhang, Jun Guo, Hong Liao, Aiping Zhou, Jian Huang, Bin Hu, Jun Li, Xianling Liu, Qingyun Zhang, Shusuan Jiang, Ziling Liu
article en
27 citations

Abstract

Disitamab vedotin-toripalimab led to a significantly greater improvement in outcomes than chemotherapy among patients with untreated HER2-expressing locally advanced or metastatic urothelial cancer. (Funded by RemeGen and others; RC48-C016 ClinicalTrials.gov number, NCT05302284; ChinaDrugTrials.org.cn number, CTR20220348.).

New England Journal of MedicineVol. 393(23)
Qingdao University (CN), Tongji University (CN), Fujian Medical University (CN), Central South University (CN), Guiyang Medical University (CN), Sun Yat-sen University (CN), Chongqing University (CN), Guangxi Medical University (CN), Yantai University (CN), Jilin University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), National Cancer Center (US), Sun Yat-sen Memorial Hospital (CN), Shandong Tumor Hospital (CN), Affiliated Hospital of Guizhou Medical University (CN), Hunan Cancer Hospital (CN), Affiliated Hospital of Qingdao University (CN), Sichuan Cancer Hospital (CN), First Affiliated Hospital of Fujian Medical University (CN), First Hospital of Jilin University (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Peking University First Hospital (CN), Zhejiang Provincial People's Hospital (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Ministry of Education (ET), Second Xiangya Hospital of Central South University (CN), Chongqing Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Shandong First Medical University (CN), First Affiliated Hospital Zhejiang University (CN), Chongqing Medical University (CN)
Openalex Percentile: Top 0%
Bladder and Urothelial Cancer Treatments
54.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.